Stem Cell Reviews and Reports

, Volume 9, Issue 1, pp 93–109 | Cite as

Systemic Delivery of Human Mesenchymal Stromal Cells Combined with IGF-1 Enhances Muscle Functional Recovery in LAMA2 dy/2j Dystrophic Mice

  • Mariane Secco
  • Carlos BuenoJr
  • Natassia M. Vieira
  • Camila Almeida
  • Mayra Pelatti
  • Eder Zucconi
  • Paolo Bartolini
  • Mariz Vainzof
  • Elen H. Miyabara
  • Oswaldo K. Okamoto
  • Mayana ZatzEmail author


The combination of cell therapy with growth factors could be a useful approach to treat progressive muscular dystrophies. Here, we demonstrate, for the first time, that IGF-1 considerably enhances the myogenesis of human umbilical cord (UC) mesenchymal stromal cells (MSCs) in vitro and that IGF-1 enhances interaction and restoration of dystrophin expression in co-cultures of MSCs and muscle cells from Duchenne patients. In vivo studies showed that human MSCs were able to reach the skeletal muscle of LAMA2 dy/2j dystrophic mice, through systemic delivery, without immunosuppression. Moreover, we showed, for the first time, that IGF-1 injected systemically together with MSCs markedly reduced muscle inflammation and fibrosis, and significantly improved muscle strength in dystrophic mice. Our results suggest that a combined treatment with IGF-1 and MSCs enhances efficiency of muscle repair and, therefore, should be further considered as a potential therapeutic approach in muscular dystrophies.


Muscular dystrophies IGF-1 Mesenchymal stromal cells 



Members from University Hospital, Constancia Urbani, Marcos Valadares, Tatiana Jazedje, Estela Cruvinel, Carla Freitas, Juliana Gomes, Amanda Assoni, Gabriela Polster, Heloisa Caetano, Tabata Leal, Maria Neide Mascarenhas, Miriam Suzuki, Paula Onofre, Marta Canovas, Fernando Luis Molina and Maria Rita Passos-Bueno are gratefully acknowledged for support and for helpful suggestions. We would like to thank Dr. Glenn Morris from the Center for Inherited Neuromuscular Disease (CIND) - UK for providing anti-human dystrophin antibody. This work was supported with grants of CEPID-FAPESP (Centro de Pesquisa, Inovação e Difusão-Fundação de Amparo a Pesquisa do Estado de São Paulo), CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), INCT (Instituto Nacional de Ciência e Tecnologia). The authors indicate no potential conflicts of interest.


The authors indicate no potential conflicts of interest.


  1. 1.
    Emery, A. E. (2002). The muscular dystrophies. Lancet, 359, 687–695.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Brien, K. F., & Kunkel, L. M. (2001). Dystrophin and muscular dystrophy: past, present, and future. Molecular Genetics and Metabolism, 74, 75–88.PubMedCrossRefGoogle Scholar
  3. 3.
    Dubowitz, V. (1999). 68th ENMC international workshop: on congenital muscular dystrophy, 9–11, April 1999 Naarden, The Netherlands. Neuromuscular Disorders, 9, 446–454.PubMedCrossRefGoogle Scholar
  4. 4.
    Dalkilic, I., & Kunkel, L. M. (2003). Muscular dystrophies: genes to pathogenesis. Current Opinion in Genetics & Development, 13, 231–238.CrossRefGoogle Scholar
  5. 5.
    Kumar, A., Yamauchi, J., Girgenrath, T., & Girgenrath, M. (2011). Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Human Molecular Genetics, 20, 2333–2343.PubMedCrossRefGoogle Scholar
  6. 6.
    Chamberlain, J. R., & Chamberlain, J. S. (2010). Muscling in: gene therapies for muscular dystrophy target RNA. Nature Medicine, 16, 170–171.PubMedCrossRefGoogle Scholar
  7. 7.
    Kerkis, I., Ambrosio, C. E., Kerkis, A., et al. (2008). Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: local or systemic? Journal of Translational Medicine, 6, 35.PubMedCrossRefGoogle Scholar
  8. 8.
    Vieira, N. M., Bueno, C. R., Brandalise, V., et al. (2008). Sjl dystrophic mice express a significant amount of human muscle proteins following systemic delivery of human adipose-derived stromal cells without immunosupression. Stem Cells, 26, 2391–2398.PubMedCrossRefGoogle Scholar
  9. 9.
    Gang, E. J., Darabi, R., Bosnakovski, D., et al. (2009). Engraftment of mesenchymal stem cells into dystrophin-deficient mice is not accompanied by functional recovery. Experimental Cell Research, 315, 2624–2636.PubMedCrossRefGoogle Scholar
  10. 10.
    Vieira, N. M., Zucconi, E., Bueno, C. R., et al. (2010). Human multipotent mesenchymal stromal cells from distinct sources show different in vivo potential to differentiate into muscle cells when injected in dystrophic mice. Stem Cell Reviews and Reports, 6, 560–566.PubMedCrossRefGoogle Scholar
  11. 11.
    Vieira, N. M., Valadares, M., Zucconi, E., et al. (2011). Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosupression are able to reach the host muscle and express human dystrophin. Cell Transplantation. doi: 10.3727/096368911X603648.
  12. 12.
    Nitahara-Kasahara, Y., Hayashita-Kinoh, H., Ohshima-Hosoyama, S., et al. (2012). Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with duchenne muscular dystrophy. Molecular Therapy, 20, 168–177.PubMedCrossRefGoogle Scholar
  13. 13.
    da Justa Pinheiro, C. H., de Queiroz, J. C., Guimarães-Ferreira, L., et al. (2011). Local injections of adipose-derived mesenchymal stem cells modulate inflammation and increase angiogenesis ameliorating the dystrophic phenotype in dystrophin-deficient skeletal muscle. Stem Cell Reviews and Reports. doi: 10.1007/s12015-011-9304-0.
  14. 14.
    Zucconi, E., Vieira, N. M., Bueno, C. R., et al. (2011). Preclinical studies with umbilical cord mesenchymal stromal cells in different animal models for muscular dystrophy. Journal of Biomedicine and Biotechnology. doi: 10.1155/2011/715251.
  15. 15.
    Gang, E. J., Bosnakovski, D., Simsek, T., To, K., & Perlingeiro, R. C. (2008). Pax3 activation promotes the differentiation of mesenchymal stem cells toward the myogenic lineage. Experimental Cell Research, 314, 1721–1733.PubMedCrossRefGoogle Scholar
  16. 16.
    Goudenege, S., Pisani, D. F., Wdziekonski, B., et al. (2009). Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD. Molecular Therapy, 17, 1064–1072.PubMedCrossRefGoogle Scholar
  17. 17.
    Kocaefe, C., Balci, D., Hayta, B. B., & Can, A. (2010). Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. Stem Cell Reviews and Reports, 6, 512–522.PubMedCrossRefGoogle Scholar
  18. 18.
    Wagner, J., Kean, T., Young, R., Dennis, J. E., & Caplan, A. I. (2009). Optimizing mesenchymal stem cell-based therapeutics. Current Opinion in Biotechnology, 20, 531–536.PubMedCrossRefGoogle Scholar
  19. 19.
    Mourkioti, F., & Rosenthal, N. (2005). IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends in Immunology, 26, 535–542.PubMedCrossRefGoogle Scholar
  20. 20.
    Lynch, G. S., Cuffe, S. A., Plant, D. R., & Gregorevic, P. (2011). IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Neuromuscular Disorders, 11, 260–268.CrossRefGoogle Scholar
  21. 21.
    Gregorevic, P., Plant, D. R., Leeding, K. S., Bach, L. A., & Lynch, G. S. (2002). Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. American Journal of Pathology, 161, 2263–2272.PubMedCrossRefGoogle Scholar
  22. 22.
    Barton, E. R., Morris, L., Musaro, A., Rosenthal, N., & Sweeney, H. L. (2002). Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. The Journal of Cell Biology, 157, 137–148.PubMedCrossRefGoogle Scholar
  23. 23.
    Gregorevic, P., Plant, D. R., & Lynch, G. S. (2004). Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle & Nerve, 30, 295–304.CrossRefGoogle Scholar
  24. 24.
    Gehrig, S. M., Ryall, J. G., Schertzer, J. D., & Lynch, G. S. (2008). Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Experimental Physiology, 93, 1190–1198.PubMedCrossRefGoogle Scholar
  25. 25.
    Sacco, A., Doyonnas, R., LaBarge, M. A., et al. (2005). IGF-I increases bone marrow contribution to adult skeletal muscle and enhances the fusion of myelomonocytic precursors. The Journal of Cell Biology, 171, 483–492.PubMedCrossRefGoogle Scholar
  26. 26.
    Pelosi, L., Giacinti, C., Nardis, C., et al. (2007). Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. The FASEB Journal, 21, 1393–1402.CrossRefGoogle Scholar
  27. 27.
    Mills, P., Dominique, J. C., Lafrenière, J. F., Bouchentouf, M., & Tremblay, J. P. (2007). A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. American Journal of Transplantation, 7, 2247–2259.PubMedCrossRefGoogle Scholar
  28. 28.
    Secco, M., Zucconi, E., Vieira, N. M., et al. (2008). Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells, 26, 146–150.PubMedCrossRefGoogle Scholar
  29. 29.
    Vieira, N. M., Brandalise, V., Zucconi, E., et al. (2008). Human multipotent adipose-derived stem cells restore dystrophin expression of Duchenne skeletal-muscle cells in vitro. Biology of the Cell, 100, 231–241.PubMedCrossRefGoogle Scholar
  30. 30.
    Vainzof, M., Ayub-Guerrieri, D., Onofre, P. C., et al. (2008). Animal models for genetic neuromuscular diseases. Journal of Molecular Neuroscience, 34, 241–248.PubMedCrossRefGoogle Scholar
  31. 31.
    Zatz, M., Zucconi, E., Valadares, M., & Jazedje, T. (2010). Phenotypes in golden retriever. Neuromuscular Disorders, 20, 71.PubMedCrossRefGoogle Scholar
  32. 32.
    Zucconi, E., Valadares, M. C., Vieira, N. M., et al. (2010). Ringo: discordance between the molecular and clinical manifestation in a golden retriever muscular dystrophy dog. Neuromuscular Disorders, 20, 64–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Ichim, T. E., Alexandrescu, D. T., Solano, F., et al. (2010). Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cellular Immunology, 260, 75–82.PubMedCrossRefGoogle Scholar
  34. 34.
    English, K., French, A., & Wood, K. J. (2010). Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell, 7, 431–442.PubMedCrossRefGoogle Scholar
  35. 35.
    Caplan, A. I., & Correa, D. (2011). The MSC: an injury drugstore. Cell Stem Cell, 9, 11–15.PubMedCrossRefGoogle Scholar
  36. 36.
    Gharaibeh, B., Lavasani, M., Cummins, J. H., & Huard, J. (2011). Terminal differentiation is not a major determinant for the success of stem cell therapy - cross-talk between muscle-derived stem cells and host cells. Stem Cell Research & Therapy, 2, 31.CrossRefGoogle Scholar
  37. 37.
    Ohnishi, S., Sumiyoshi, H., Kitamura, S., & Nagaya, N. (2007). Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Letters, 581, 3961–3966.PubMedCrossRefGoogle Scholar
  38. 38.
    Lee, M. J., Jung, J., Na, K. H., et al. (2010). Anti-fibrotic effect of chorionic plate-derived mesenchymal stem cells isolated from human placenta in a rat model of CCl(4)-injured liver: potential application to the treatment of hepatic diseases. Journal of Cellular Biochemistry, 111, 1453–1463.PubMedCrossRefGoogle Scholar
  39. 39.
    Scicchitano, B. M., Rizzuto, E., & Musarò, A. (2009). Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1. Aging (Albany NY), 1, 451–457.Google Scholar
  40. 40.
    Wingertzahn, M. A., Zdanowicz, M. M., & Slonim, A. E. (1998). Insulin-like growth factor-I and high protein diet decrease calpain-mediated proteolysis in murine muscular dystrophy. Proceedings of the Society for Experimental Biology and Medicine, 218, 244–250.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Mariane Secco
    • 1
  • Carlos BuenoJr
    • 1
  • Natassia M. Vieira
    • 1
  • Camila Almeida
    • 1
  • Mayra Pelatti
    • 1
  • Eder Zucconi
    • 1
  • Paolo Bartolini
    • 2
  • Mariz Vainzof
    • 1
  • Elen H. Miyabara
    • 3
  • Oswaldo K. Okamoto
    • 1
  • Mayana Zatz
    • 1
    Email author
  1. 1.Human Genome Research Center, Department of Genetic and Evolutionary BiologyInstitute of BiosciencesSão PauloBrazil
  2. 2.Department of BiotechnologyNational Nuclear Energy Commission-IPEN-CNENSão PauloBrazil
  3. 3.Department of AnatomyInstitute of Biomedical Sciences, University of São PauloSão PauloBrazil

Personalised recommendations